Sanofi

Sanofi has avoided a European Union antitrust fine after the bloc accepted its offer to stop practices that disparaged a competitor's vaccine. The case concerned the French pharmaceutical giant's conduct in promoting its own vaccine while undermining a rival product. The settlement closes the investigation without financial penalty, drawing attention to how EU regulators handle vaccine market competition.

Sanofi was suspected of disparaging a rival company's flu vaccine, and the European Commission in Brussels has dropped the case without imposing a colossal fine. In exchange, the French pharmaceutical giant has offered commitments on its conduct. Separately, JP Morgan rates the stock neutral, keeping investor attention on the company.

Sanofi will not pay a fine after the European Commission accepted its offer of commitments to close an antitrust investigation. The probe examined whether the French drugmaker disparaged a rival vaccine to protect its own products. By offering remedies, Sanofi ended the case without an admission of wrongdoing or a financial penalty.

Sanofi has avoided a European Union fine in a case concerning allegations that it disparaged CSL's influenza vaccine. The decision closes a competition-related complaint against the French drugmaker over its marketing conduct in the EU flu vaccine market, where it competes directly with CSL's products. The outcome spares Sanofi a financial penalty and will be watched closely by vaccine rivals.

EU antitrust regulators have accepted concessions offered by Sanofi, closing an investigation into the French drugmaker's vaccine marketing practices. Under the settlement, Sanofi commits to changes in how it promotes its vaccines to competitors and healthcare buyers, avoiding a formal finding of infringement and potential fines. The case is part of broader European scrutiny of pharmaceutical marketing tactics.

French drugmaker Sanofi has escaped a European Commission fine after offering legally binding commitments to stop disparaging a rival vaccine. The EU antitrust regulator accepted the company's pledge, closing the case without a financial penalty. The settlement ends a probe into Sanofi's conduct against a competitor's vaccine, and the commitment is now binding on the company across the bloc.

European Union regulators have accepted concessions offered by Sanofi to close an antitrust investigation into the French drugmaker's vaccine marketing practices. The settlement means the EU competition inquiry ends without a fine or formal finding of infringement, with Sanofi committing to changes in how it markets its vaccines. The case is the latest in a series of EU antitrust actions targeting pharmaceutical marketing tactics.

European Union antitrust regulators have accepted concessions offered by Sanofi, allowing them to close an investigation into the French drugmaker's conduct in the vaccines market. The European Commission had been probing whether Sanofi's practices breached competition rules. By agreeing to the commitments, Sanofi avoids a formal finding of infringement and potential fines, ending one of the EU's higher-profile pharmaceutical competition cases.